Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers

Published on Jun 9, 2011in The New England Journal of Medicine70.67
· DOI :10.1056/NEJMoa1009370
Sanjeev Arora24
Estimated H-index: 24
Karla Thornton10
Estimated H-index: 10
+ 12 AuthorsClifford R. Quails50
Estimated H-index: 50
Methods We conducted a prospective cohort study comparing treatment for HCV infection at the University of New Mexico (UNM) HCV clinic with treatment by primary care clinicians at 21 ECHO sites in rural areas and prisons in New Mexico. A total of 407 patients with chronic HCV infection who had received no previous treatment for the infection were enrolled. The primary end point was a sustained virologic response. Results A total of 57.5% of the patients treated at the UNM HCV clinic (84 of 146 patients) and 58.2% of those treated at ECHO sites (152 of 261 patients) had a sustained viral response (difference in rates between sites, 0.7 percentage points; 95% confidence interval, −9.2 to 10.7; P = 0.89). Among patients with HCV genotype 1 infection, the rate of sustained viral response was 45.8% (38 of 83 patients) at the UNM HCV clinic and 49.7% (73 of 147 patients) at ECHO sites (P = 0.57). Serious adverse events occurred in 13.7% of the patients at the UNM HCV clinic and in 6.9% of the patients at ECHO sites. Conclusions The results of this study show that the ECHO model is an effective way to treat HCV infection in underserved communities. Implementation of this model would allow other states and nations to treat a greater number of patients infected with HCV than they are currently able to treat. (Funded by the Agency for Healthcare Research and Quality and others.)
  • References (24)
  • Citations (429)
📖 Papers frequently viewed together
16 Authors (Sanjeev Arora, ..., Wesley Pak)
159 Citations
15 Authors (Sanjeev Arora, ..., Sean Yutzy)
136 Citations
1,683 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
The Patient Protection and Affordable Care Act enables community health centers to serve nearly 20 million new patients while adding an estimated 15,000 providers to their staffs by 2015. Dr. Eli Adashi and colleagues describe the “new” community health centers.
141 CitationsSource
#1Michael L. Volk (UM: University of Michigan)H-Index: 28
#2Rachel S. Tocco (UM: University of Michigan)H-Index: 4
Last. Anna S. Lok (UM: University of Michigan)H-Index: 86
view all 4 authors...
Despite dramatic improvements in antiviral therapy for hepatitis C, there is reason to believe that the uptake of antiviral therapy remains limited. The aims of this study were to determine the number of patients being treated with antiviral therapy in the U.S., to estimate the public health impact of these treatment patterns, and to identify barriers to treatment for patients with hepatitis C. Data on the number of new patient pegylated interferon prescriptions each year, from 2002–2007, was ob...
197 CitationsSource
Purpose Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. Incidence rates are increasing in the United States. Monitoring incidence, survival, and mortality rates within at-risk populations can facilitate control efforts. Methods Age-adjusted incidence trends for HCC were examined in the Surveillance, Epidemiology, and End Results (SEER) registries from 1975 to 2005. Age-specific rates were examined for birth cohorts born between 1900 and 1959. Age-adjusted...
1,115 CitationsSource
#1Maribel Rodriguez-Torres (Ponce Health Sciences University)H-Index: 36
#2Lennox J Jeffers (UM: University of Miami)H-Index: 44
Last. Paul L. Martin (Hoffmann-La Roche)H-Index: 128
view all 7 authors...
Background Race has been shown to be a factor in the response to therapy for hepatitis C virus (HCV) infection, and limited data suggest that ethnic group may be as well; however, Latinos and other ethnic subpopulations have been underrepresented in clinical trials. We evaluated the effect of Latino ethnic background on the response to treatment with peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who had not been treated previously. Methods In a multicenter, open-la...
164 CitationsSource
#1Jennifer A. Tan (UCLA: University of California, Los Angeles)H-Index: 3
#2Tom A. Joseph (UCLA: University of California, Los Angeles)H-Index: 2
Last. Sammy Saab (UCLA: University of California, Los Angeles)H-Index: 56
view all 3 authors...
The prevalence of chronic hepatitis C infection in U.S. prisons is 12% to 31%. Treatment of this substantial portion of the population has been subject to much controversy, both medically and legally. Studies have demonstrated that treatment of chronic hepatitis C with pegylated interferon (PEG IFN) and ribavirin is a cost-effective measure in the general population; however, no study has addressed whether the same is true of the prison population. The aim of this study was to determine the cost...
58 CitationsSource
#2George N. Ioannou (UW: University of Washington)H-Index: 40
Last. Jason A. Dominitz (UW: University of Washington)H-Index: 57
view all 7 authors...
Objectives. We examined the association between race and hepatitis C virus (HCV) evaluation and treatment of veterans in the Northwest Network of the Department of Veterans Affairs (VA).Methods. In our retrospective cohort study, we used medical records to determine antiviral treatment of 4263 HCV-infected patients from 8 VA medical centers. Secondary outcomes included specialty referrals, laboratory evaluation, viral genotype testing, and liver biopsy. Multiple logistic regression was used to a...
34 CitationsSource
#1Richard B. Freeman (Tufts Medical Center)H-Index: 108
#2D. E. SteffickH-Index: 2
Last. Robert M. Merion (UM: University of Michigan)H-Index: 68
view all 6 authors...
Liver transplantation in 2006 generally resembled previous years, with fewer candidates waiting for deceased donor liver transplants (DDLT), continuing a trend initiated with the implementation of the model for end-stage liver disease (MELD). Candidate age distribution continued to skew toward older ages with fewer children listed in 2006 than in any prior year. Total transplants increased due to more DDLT with slightly fewer living donor liver transplants (LDLT). Waiting list deaths and time to...
278 CitationsSource
#1Lisa I. BackusH-Index: 22
#2Derek B. BoothroydH-Index: 29
Last. Larry A. MoleH-Index: 25
view all 4 authors...
The currently recommended treatment for hepatitis C virus (HCV) infection is pegylated interferon alfa (PEG-INF) and ribavirin, which can be difficult to tolerate. More information about predicting sustained virologic response (SVR) may allow more informed treatment decisions to be made. This retrospective observational cohort study identified predictors of SVR to PEG-INF and ribavirin in routine medical practice at 121 Department of Veterans Affairs facilities. Among 5,944 patients infected wit...
209 CitationsSource
#1Matthew E. Wise (UCLA: University of California, Los Angeles)H-Index: 27
#2Stephanie R. Bialek (CDC: Centers for Disease Control and Prevention)H-Index: 26
Last. Frank Sorvillo (UCLA: University of California, Los Angeles)H-Index: 14
view all 5 authors...
The disease burden and mortality from hepatitis C are predicted to increase in the United States as the number of persons with long-standing chronic infection grows. We analyzed hepatitis C mortality rates derived from US Census and multiple-cause-of-death data for 1995-2004. Deaths were considered hepatitis C–related if: (1) hepatitis C was the underlying cause of death, (2) chronic liver disease was the underlying cause and hepatitis C was a contributing cause, or (3) human immunodeficiency vi...
191 CitationsSource
#1Fasiha Kanwal (SLU: Saint Louis University)H-Index: 42
#2Tuyen HoangH-Index: 13
Last. Steven M. Asch (UCLA: University of California, Los Angeles)H-Index: 64
view all 8 authors...
Treatment with interferon and ribavirin is effective in patients with chronic infection with hepatitis C virus (HCV). Previous data indicate that treatment rates are suboptimal. We sought to identify patient and provider-level predictors of treatment receipt in HCV by conducting a retrospective cohort study of 5701 HCV patients in a large regional Veteran’s Administration (VA) healthcare network. We also determined the degree of variation in treatment rates attributable to patient, provider, and...
109 CitationsSource
Cited By429
#1E. Michael LewieckiH-Index: 47
#2Micol S. Rothman (University of Colorado Denver)H-Index: 10
#1Ezequiel Mauro (Hospital Italiano de Buenos Aires)H-Index: 2
#2Sebastián Marciano (Hospital Italiano de Buenos Aires)H-Index: 10
Last. Adrián Gadano (Hospital Italiano de Buenos Aires)H-Index: 32
view all 6 authors...
Abstract Aims Telemedicine between healthcare providers could be useful for improving access to hepatology consultations, which is challenging in some regions. The primary objective of this study was to estimate the proportion of consultations that were resolved through a telemedicine program. Additionally, we evaluated patient satisfaction with this strategy. Methods Consecutive telemedicine consultations made by non-hepatologist healthcare providers from different regions of Argentina to a spe...
#1Brian J. LevineH-Index: 2
#2Kelly L. CloseH-Index: 9
Last. David M. Maahs (Stanford University)H-Index: 49
view all 11 authors...
Abstract In June 2019, the Leona M. and Harry B. Helmsley Charitable Trust and JDRF International (JDRF) co-sponsored the Healthcare Professional Resource Workshop in San Francisco, California. The workshop convened stakeholders in the diabetes field in order to: [1] review information and resources created for healthcare professionals (HCPs) caring for people with diabetes on intensive insulin therapy; [2] share knowledge to scale and decentralize diabetes care; [3] identify synergies across th...
#1Jad BakiH-Index: 2
Last. Elliot B. TapperH-Index: 11
view all 3 authors...
Abstract NIMHANS ECHO (Extension for Community Healthcare Outcomes) model uses a video conferencing app to connect multiple community health care teams simultaneously with addiction treatment specialists and builds treatment capacity via mentorship and case-based learning. The aim was to investigate the characteristics of 102 cases discussed by remote community health providers in 28 weekly tele-ECHO addiction clinics between January to July 2019. Among the presented cases, the lifetime and curr...
#1Brian Kirmse (UMMC: University of Mississippi Medical Center)H-Index: 8
#1David M. Hachey PharmD (ISU: Idaho State University)H-Index: 2
#1David M. Hachey (ISU: Idaho State University)H-Index: 2
Last. Nicki L. Aubuchon-Endsley (ISU: Idaho State University)H-Index: 7
view all 3 authors...
Hepatitis C (HCV) care cascades have been described in diverse clinical settings, patient populations and countries, highlighting the steps in HCV care where improvements can be made and resources allocated. However, more research is needed to examine barriers to HCV treatment in rural, underserved populations and in Federally Qualified Health Centers (FQHCs). As part of a quality improvement (QI) project, this study aimed to describe and evaluate the HCV treatment cascade in an FQHC serving a l...
People with type 1 diabetes may receive a significant portion of their care from primary care providers (PCPs). To understand the involvement of PCPs in delivering type 1 diabetes care, we performed surveys in California and Florida, two of the most populous and diverse states in the United States. PCPs fill insulin prescriptions but report low confidence in providing type 1 diabetes care and difficulty accessing specialty referrals to endocrinologists.
1 CitationsSource
#2Poonam MathurH-Index: 7
#1Micah O. Mazurek (UVA: University of Virginia)H-Index: 23
#2Robert A. Parker (Harvard University)H-Index: 57
Last. Kristin Sohl (MU: University of Missouri)H-Index: 6
view all 5 authors...
Importance The Extension for Community Health Outcomes (ECHO) model is a widely adopted technology-based model for training primary care physicians and practitioners (PCPs) to care for patients with complex conditions. Despite its popularity, to our knowledge, direct effects of ECHO on clinical practice have not been tested in a large-scale study. Objective To test the effectiveness of the ECHO model as applied to primary care for autism and whether it resulted in improved clinical practice, kno...